Discover the top 36 companies transforming the pharmaceutical contract manufacturing market, including Thermo Fisher Scientific Inc., Lonza, Catalent, Inc., and other industry leaders. Backed by a market projected to grow from $209.90 billion to $311.95 billion by 2030 at a CAGR of 8.2%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Pharmaceutical Contract Manufacturing Companies

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a global leader in the pharmaceutical contract manufacturing market, offering an integrated suite of drug development and clinical services through its premier brands, including Patheon and PPD. The company provides end-to-end CDMO and CRO solutions, streamlining the journey from early-stage research and pre-clinical testing to clinical trial management and commercial manufacturing. With annual revenues exceeding $40 billion, Thermo Fisher leverages extensive laboratory services, AI-enabled digital solutions, and global clinical supply chain capabilities to help biopharmaceutical and medical device customers increase productivity and bring innovative therapies to market with greater speed and efficiency.

Lonza

Lonza is a prominent global development and manufacturing partner for the pharmaceutical, biotech, and nutrition markets. Headquartered in Switzerland, the company maintains a strong position in the CDMO sector with extensive biologics manufacturing capacity and strategic site acquisitions. Lonza provides a comprehensive range of services across various modalities, including small molecules, biologics, and cell and gene therapies. The company is recognized for its investment in innovative production technologies for complex biologics and its ability to support customers from early-stage development through to large-scale commercial production.

Catalent, Inc.

Catalent, Inc. is a well-established CDMO that delivers development and manufacturing solutions for medicines, biologics, and consumer health products. The company is known for its sophisticated delivery methods, including oral, injectable, and respiratory delivery systems. Catalent supports the pharmaceutical and biotechnology sectors by providing clinical supply services and commercial manufacturing capabilities across a global network of facilities. Its expertise in formulation and advanced delivery technologies positions it as a key partner for companies seeking to optimize the performance and market reach of their therapeutic products.

WuXi AppTec

WuXi AppTec is a leading global provider of R&D and manufacturing services that enable companies in the pharmaceutical, biotech, and medical device industries to advance discoveries and deliver groundbreaking treatments. The company offers a broad portfolio of services through its integrated platforms, including small molecule R&D and manufacturing, cell and gene therapy services, and drug metabolism and pharmacokinetics (DMPK) testing. WuXi AppTec’s “CRDMO” model integrates contract research, development, and manufacturing organizations to provide seamless support throughout the entire drug development lifecycle.

WuXi Biologics

WuXi Biologics is a global contract research, development, and manufacturing organization (CRDMO) specializing in biologics. The company provides open-access technology platforms for biologics discovery, development, and manufacturing, supporting partners from initial concept to commercial production. WuXi Biologics is recognized for its “Global Dual Sourcing” strategy and its commitment to innovation in bioprocessing, including the use of single-use bioreactors. Its extensive capacity and technical expertise make it a primary partner for biopharmaceutical companies developing monoclonal antibodies, recombinant proteins, and vaccines.

Samsung Biologics

Samsung Biologics is a leading fully integrated CDMO based in South Korea, specializing in the development and manufacturing of biological products. The company operates some of the world’s largest biologics manufacturing facilities, offering high-capacity stainless steel bioreactors and advanced single-use technology. Samsung Biologics provides end-to-end services including cell line development, process development, and large-scale commercial manufacturing. Its focus on operational excellence and rapid facility expansion has established it as a critical player in meeting the global demand for high-quality monoclonal antibodies and other complex biologics.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim is a global, research-driven pharmaceutical company that also operates one of the world’s leading CDMO businesses for biologics, known as Boehringer Ingelheim BioXcellence. The company provides a full range of services for the development and manufacture of therapeutic proteins, including monoclonal antibodies, fusion proteins, and DNA-based therapeutics. With state-of-the-art facilities in Europe, the U.S., and China, Boehringer Ingelheim offers customers access to extensive technical expertise and a proven track record in navigating complex regulatory landscapes for global market supply.

Evonik

Evonik is a global leader in specialty chemicals and a significant player in the pharmaceutical CDMO market, particularly through its Health Care business line. The company specializes in the development and manufacturing of complex active pharmaceutical ingredients (APIs) and intermediates, with a strong focus on high-potency APIs and specialized drug delivery technologies. Evonik is a major partner for the pharmaceutical industry in the field of lipid nanoparticle (LNP) technology and functional polymers for controlled-release formulations, supporting the development of advanced drug delivery systems for mRNA vaccines and other innovative therapies.

Fujifilm Holdings Corporation

Fujifilm Holdings Corporation, through its subsidiary Fujifilm Diosynth Biotechnologies, is a world-leading CDMO for biologics, viral vectors, and vaccines. The company provides comprehensive development and manufacturing services across a variety of expression systems, including mammalian, microbial, and insect cells. Fujifilm has made significant investments in expanding its global manufacturing footprint, particularly in large-scale cell culture and advanced therapy medicinal products (ATMPs). Its focus on “Partnership for Life” emphasizes long-term collaboration and technical innovation to accelerate the delivery of life-changing medicines.

AbbVie Inc.

AbbVie Inc., through its AbbVie Contract Manufacturing division, leverages its internal manufacturing expertise to provide CDMO services to the broader pharmaceutical industry. The company offers a diverse range of capabilities, including the production of potent APIs, drug products, and biologics. AbbVie’s contract manufacturing services are supported by a global network of facilities with extensive experience in scaling complex manufacturing processes and ensuring high-quality supply. Its expertise in specialized areas like hot-melt extrusion and fermentation positions it as a valuable partner for companies with challenging drug development programs.

Download PDF Brochure:“Click Here”